- Oral presentation
- Open Access
O412 Factors associated with poor clinical outcome among HIV-infected patients with tuberculosis (TB) in Europe and Argentina. The HIV/TB collaborative study
© Podlekareva et al; licensee BioMed Central Ltd. 2008
- Published: 10 November 2008
- Relative Hazard
- Health Attention
- O412 Factor
- Adjusted Relative Hazard
TB is a common and potentially fatal co-infection among HIV-infected patients worldwide. We aimed to evaluate potential regional differences in patient characteristics and clinical management and their influence on the one-year mortality rate after a TB diagnosis in HIV-infected patients across Europe and Argentina.
1,075 consecutive HIV-patients who started treatment for TB between January 2004 and December 2006 in 47 clinics across Europe and Argentina were identified. Patients were stratified according to region of residence: Argentina (A), Southern Europe (S), Central/Northern Europe (CN), or Eastern Europe (E). Deaths among HIV/TB co-infected patients within 12 months of TB diagnosis, and factors associated with death, were analysed.
A (n = 115)
S (n = 210)
CN (n = 168)
E (n = 582)
Injecting drug use (%)
>4 1st line anti-TB drugs in initial regimen (%)
>1 2nd line anti-TB drug in initial regimen (%)
Resistance to any anti-TB drug (%, 513 tests)
CD4 count at TB diagnosis (cells/mm3, median, inter-quartile range)
On cART at TB diagnosis (%)
On cART 12 months after TB diagnosis (%)
In conclusion, there were substantial differences in the clinical management of HIV-TB co-infected patients across Europe and Argentina, including less use of cART and more extensive use of second-line anti-TB drugs, presumably partly due to widespread TB drug resistance in populations from E. These factors may partly explain the 3–4 fold higher one-year mortality rate after a TB diagnosis in this region, and deserve immediate public health attention.
This article is published under license to BioMed Central Ltd.